Celgene Joins Evotec In Its First Neurodegenerative Drug Discovery Effort
Evotec has landed a strategic partnership with Celgene worth up to $295m in neurodegeneration drug discovery based on the German CRO's induced pluripotent stem cell platform.
Evotec has landed a strategic partnership with Celgene worth up to $295m in neurodegeneration drug discovery based on the German CRO's induced pluripotent stem cell platform.